Home›Trial›NCT04824092
🔬NCT04824092Phase 3ACTIVE NOT RECRUITING

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Study Summary

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Conditions
Diffuse Large B-cell Lymphoma
Interventions / Drugs
TafasitamabLenalidomideRituximabCyclophosphamideDoxorubicinVincristinePrednisoneTafasitamab placeboLenalidomide placebo
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
C60/100
Study Details
Enrollment899 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647267+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.